Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us?

Eyre, 2022, CNS prophylaxis for diffuse large B-cell lymphoma, Lancet Oncol, 23, e416, 10.1016/S1470-2045(22)00371-0 Ferreri, 2015, Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era, Br J Haematol, 168, 654, 10.1111/bjh.13194 Faqah, 2021, Real-world data (RWD) on the 3-year follow-up outcomes of different CNS prophylaxis strategies across CNS-IPI risk groups in patients with diffuse large B-cell non-Hodgkin lymphoma, JCO Glob Oncol, 486, 10.1200/GO.20.00422 Green, 2022, Central nervous system lymphoma, Curr Diagn Pathol, 3, 45 Ruppert, 2020, International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI, Blood, 135, 2041, 10.1182/blood.2019002729 Project TIN-HLPF, 1993, 329, 987 Batchelor, 2011, Rituximab monotherapy for patients with recurrent primary CNS lymphoma, Neurology, 76, 929, 10.1212/WNL.0b013e31820f2d94 Kridel, 2017, Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era, Br J Haematol, 176, 210, 10.1111/bjh.14392 Feugier, 2004, Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab, Ann Oncol, 15, 129, 10.1093/annonc/mdh013 Villa, 2010, Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy, Ann Oncol, 21, 1046, 10.1093/annonc/mdp432 Schmitz, 2016, CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP, J Clin Oncol, 34, 3150, 10.1200/JCO.2015.65.6520 El-Galaly, 2017, The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: an international multicenter study of 1532 patients treated with chemoimmunotherapy, Eur J Cancer, 75, 195, 10.1016/j.ejca.2016.12.029 Savage, 2014, Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma, Blood, 124, 394, 10.1182/blood.V124.21.394.394 Schmitz, 2016, CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP, J Clin Oncol, 34, 3150, 10.1200/JCO.2015.65.6520 Ong, 2020, Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia, Leuk Lymphoma, 61, 225, 10.1080/10428194.2019.1648805 Savage, 2016, Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL, Blood, 127, 2182, 10.1182/blood-2015-10-676700 Klanova, 2019, Integration of cell of origin into the clinical CNS international prognostic index improves CNS relapse prediction in DLBCL, Blood, 133, 919, 10.1182/blood-2018-07-862862 Snuderl, 2010, B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma, Am J Surg Pathol, 34, 327, 10.1097/PAS.0b013e3181cd3aeb Oki, 2014, Double hit lymphoma: the MD Anderson Cancer Center clinical experience, Br J Haematol, 166, 891, 10.1111/bjh.12982 Epperla, 2022, High-grade B-cell lymphoma, not otherwise specified (HGBL, NOS): central nervous system (CNS) involvement, prophylaxis, and recurrence risk in a multi-institutional series, Blood, 140, 3839, 10.1182/blood-2022-157105 Miyazaki, 2011, CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab, Ann Oncol, 22, 1601, 10.1093/annonc/mdq627 Hosein, 2014, A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era, Br J Haematol, 165, 358, 10.1111/bjh.12753 Law, 2023 Haioun, 2000, Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients, Ann Oncol, 11, 685, 10.1023/A:1008394827806 Arkenau, 2007, The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma, Ann Oncol, 18, 541, 10.1093/annonc/mdl434 Ferreri, 2017, Prophylaxis with high-dose methotrexate significantly reduces CNS dissemination in patients with diffuse large B-cell lymphoma (DLBCL) and high-risk CNS-IPI score, Hematol Oncol, 35, 198, 10.1002/hon.2438_60 Cheah, 2014, A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma, Br J Cancer, 111, 1072, 10.1038/bjc.2014.405 Phillips, 2016, Low rates of CNS relapse in high risk DLBCL patients treated with R-CODOX-M and R-IVAC: results from a phase 2 UK NCRI/bloodwise trial, Blood, 128, 1855, 10.1182/blood.V128.22.1855.1855 Holte, 2012, Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic lymphoma group study, Ann Oncol, 24, 1385, 10.1093/annonc/mds621 Vitolo, 2011, First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial, J Clin Oncol, 29, 2766, 10.1200/JCO.2010.31.4187 Conconi, 2021, Intensified (intravenous and intrathecal) CNS prophylaxis in primary testicular diffuse large b-cell lymphoma: 5-year results of the IELSG30 trial, Hematol Oncol, 39 Jeong, 2021, Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis, Blood Adv, 5, 2142, 10.1182/bloodadvances.2020003947 Howard, 2023 Amitai, 2020, Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies, Hematol Oncol, 38, 584, 10.1002/hon.2759 Kawaguchi, 2021, Risk factors for high-dose methotrexate-induced nephrotoxicity, Int J Hematol, 114, 79, 10.1007/s12185-021-03132-8 Wiczer, 2015, 22, 430 Li, 2021, Improvement of outcomes of an escalated high&#x2010;dose methotrexate-based regimen for patients with newly diagnosed primary central nervous system lymphoma: a real-world cohort study, Cancer Manag Res, 13, 6115, 10.2147/CMAR.S322467 Gagliano, 1976, Paraplegia following intrathecal methotrexate report of a case and Reuiew of the Litel-atu?-e, Cancer, 37, 1663, 10.1002/1097-0142(197604)37:4<1663::AID-CNCR2820370408>3.0.CO;2-7 Pang, 2022, Intrathecal methotrexate toxicity resulting in brain death due to generalized cerebral edema case report, Neurohospitalist, 12, 697 Orellana-Noia, 2022, Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions, Blood, 139, 413, 10.1182/blood.2021012888 Wilson, 2022, Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients, Blood, 139, 2499, 10.1182/blood.2021014506 Bobillo, 2021, Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse, Blood Cancer J, 11 Hegde, 2005, High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology, Blood, 105, 496, 10.1182/blood-2004-05-1982 Alvarez, 2012, Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma, Ann Oncol, 23, 1274, 10.1093/annonc/mdr436 Lewis, 2021, High-dose methotrexate is not associated with reduction in CNS relapse in patients with aggressive B-cell lymphoma: an international retrospective study of 2300 high-risk patients, Blood, 138, 181, 10.1182/blood-2021-146737 Puckrin, 2021, Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma, Am J Hematol, 96, 764, 10.1002/ajh.26181 Klanova, 2019, Integration of cell of origin into the clinical CNS international prognostic index improves CNS relapse prediction in DLBCL, Blood, 133, 919, 10.1182/blood-2018-07-862862 Ollila, 2021, Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma, Blood, 137, 1120, 10.1182/blood.2020007236 Twa, 2021, Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma, Blood, 137, 1256, 10.1182/blood.2020006338 Chapuy, 2018, Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes, Nat Med, 24, 679, 10.1038/s41591-018-0016-8 Wright, 2020, A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications, Cancer Cell, 37, 551, 10.1016/j.ccell.2020.03.015 Chapuy, 2018, Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes, Nat Med, 24, 679, 10.1038/s41591-018-0016-8 Roschewski, 2020, Molecular classification and treatment of diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, Cancer J, 26, 195, 10.1097/PPO.0000000000000450 Wyndham Wilson, 2021, Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL, Cancer Cell, 39, 1643, 10.1016/j.ccell.2021.10.006 Bernard, 2021, Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP, Blood Adv, 5, 2965, 10.1182/bloodadvances.2021004766 Olszewski, 2020, Cerebrospinal fluid (CSF) analysis of tumor-specific cell-free DNA (cfDNA) as a diagnostic and prognostic tool for central nervous system (CNS) invasion in lymphoma, Blood, 136, 21, 10.1182/blood-2020-134757 Boehme, 2009, CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL), Blood, 113, 3896, 10.1182/blood-2008-10-182253